Cargando…
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
This review provides an overview covering mRNA from its use in the COVID-19 pandemic to cancer immunotherapy, starting from the selection of appropriate antigens, tumor-associated and tumor-specific antigens, neoantigens, the basics of optimizing the mRNA molecule in terms of stability, efficacy, an...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953480/ https://www.ncbi.nlm.nih.gov/pubmed/36830845 http://dx.doi.org/10.3390/biomedicines11020308 |
| _version_ | 1784893888272531456 |
|---|---|
| author | Krause, Werner |
| author_facet | Krause, Werner |
| author_sort | Krause, Werner |
| collection | PubMed |
| description | This review provides an overview covering mRNA from its use in the COVID-19 pandemic to cancer immunotherapy, starting from the selection of appropriate antigens, tumor-associated and tumor-specific antigens, neoantigens, the basics of optimizing the mRNA molecule in terms of stability, efficacy, and tolerability, choosing the best formulation and the optimal route of administration, to summarizing current clinical trials of mRNA vaccines in tumor therapy. |
| format | Online Article Text |
| id | pubmed-9953480 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99534802023-02-25 mRNA—From COVID-19 Treatment to Cancer Immunotherapy Krause, Werner Biomedicines Review This review provides an overview covering mRNA from its use in the COVID-19 pandemic to cancer immunotherapy, starting from the selection of appropriate antigens, tumor-associated and tumor-specific antigens, neoantigens, the basics of optimizing the mRNA molecule in terms of stability, efficacy, and tolerability, choosing the best formulation and the optimal route of administration, to summarizing current clinical trials of mRNA vaccines in tumor therapy. MDPI 2023-01-22 /pmc/articles/PMC9953480/ /pubmed/36830845 http://dx.doi.org/10.3390/biomedicines11020308 Text en © 2023 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Review Krause, Werner mRNA—From COVID-19 Treatment to Cancer Immunotherapy |
| title | mRNA—From COVID-19 Treatment to Cancer Immunotherapy |
| title_full | mRNA—From COVID-19 Treatment to Cancer Immunotherapy |
| title_fullStr | mRNA—From COVID-19 Treatment to Cancer Immunotherapy |
| title_full_unstemmed | mRNA—From COVID-19 Treatment to Cancer Immunotherapy |
| title_short | mRNA—From COVID-19 Treatment to Cancer Immunotherapy |
| title_sort | mrna—from covid-19 treatment to cancer immunotherapy |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953480/ https://www.ncbi.nlm.nih.gov/pubmed/36830845 http://dx.doi.org/10.3390/biomedicines11020308 |
| work_keys_str_mv | AT krausewerner mrnafromcovid19treatmenttocancerimmunotherapy |